ConductScience.org, home

Paper35118917

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.

Wen W and 11 others. Ann Med, 2022. Cited by 307 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Papers, record 35118917. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35118917

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
PubMed
Journal
Ann Med
PubMed
Year
2022
PubMed
Publication types
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
307
iCite
Relative citation ratio, by iCite
22.8
iCite
Revised in PubMed
2026-10-02
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wen WWen
2Chen CChen
3Tang JJiake
4Wang CChunyi
5Zhou MMengyun
6Cheng YYongran
7Zhou XXiang
8Wu QQi
9Zhang XXingwei
10Feng ZZhanhuihttps://orcid.org/0000-0003-4755-7415
11Wang MMingweihttps://orcid.org/0000-0001-9060-5107
12Mao QQin

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FluvoxamineMajor topic
COVID-19 Drug TreatmentMajor topic
Antiviral Agents
Cytidine
Drug Combinations
Humans
Hydroxylamines
Lactams
Leucine
Nitriles
Proline
Ritonavir
SARS-CoV-2

Source PubMed

Download CSV of topics

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133180097Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.JAMA2020https://conductscience.org/library/papers/33180097PubMed
233743213Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.Cell2021https://conductscience.org/library/papers/33743213PubMed
331578288Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.J Virol2019https://conductscience.org/library/papers/31578288PubMed
432321732Remdesivir in covid-19.BMJ2020https://conductscience.org/library/papers/32321732PubMed
533649113Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33649113PubMed
632253226An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.Sci Transl Med2020https://conductscience.org/library/papers/32253226PubMed
733959018Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.Front Pharmacol2021https://conductscience.org/library/papers/33959018PubMed
833863887Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.Nat Commun2021https://conductscience.org/library/papers/33863887PubMed
934754175What will be the role of molnupiravir in the treatment of COVID-19 infection?Drugs Ther Perspect2021https://conductscience.org/library/papers/34754175PubMed
1034066475Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Vaccines (Basel)2021https://conductscience.org/library/papers/34066475PubMed
1135186365Childhood Immunization Schedule for National Immunization Program Vaccines - China (Version 2021).China CDC Wkly2021https://conductscience.org/library/papers/35186365PubMed
1234717820Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.Lancet Glob Health2022https://conductscience.org/library/papers/34717820PubMed
1334607801Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports.BMJ2021https://conductscience.org/library/papers/34607801PubMed
1434641339Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.Molecules2021https://conductscience.org/library/papers/34641339PubMed
1533623808Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.Open Forum Infect Dis2021https://conductscience.org/library/papers/33623808PubMed
1633961695β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.J Infect Dis2021https://conductscience.org/library/papers/33961695PubMed
1734381216Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.Nat Struct Mol Biol2021https://conductscience.org/library/papers/34381216PubMed
1833654292SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.Nat Med2021https://conductscience.org/library/papers/33654292PubMed
1933688914CDC Interim Recommendations for Fully Vaccinated People: An Important First Step.JAMA2021https://conductscience.org/library/papers/33688914PubMed
2034118236Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.J Biol Chem2021https://conductscience.org/library/papers/34118236PubMed

See all 27 referencesDownload CSV of references

Cited by231

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 307 citations.

PMIDTitleJournalYearIn PapersSource
42653319The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages.Int J Mol Sci2026https://conductscience.org/library/papers/42653319PubMed
42353136Dual-Action Niclosamide-Polysaccharide Nasal Spray for the Early Therapeutic Intervention of Respiratory Viral Infections.Int J Mol Sci2026https://conductscience.org/library/papers/42353136PubMed
42326460Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era.ACG Case Rep J2026https://conductscience.org/library/papers/42326460PubMed
41904401CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2.Mol Med2026https://conductscience.org/library/papers/41904401PubMed
41868151Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/41868151PubMed
41788322Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis.Ther Adv Pulm Crit Care Med2026https://conductscience.org/library/papers/41788322PubMed
41676148Autophagy in emerging and highly concerned severe zoonotic infectious diseases.Front Immunol2026https://conductscience.org/library/papers/41676148PubMed
41382264Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study.BMC Infect Dis2025https://conductscience.org/library/papers/41382264PubMed
41327284CfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infection in general practice: a prospective cohort study.Virol J2025https://conductscience.org/library/papers/41327284PubMed
41200312Molecular and pathological confirmation of natural feline coronavirus infection in a captive persian leopard (Panthera pardus tulliana): Implications for Wildlife conservation and one health.Open Vet J2025https://conductscience.org/library/papers/41200312PubMed
41093342Quality and readability of drug fact sheets for FDA-approved and emergency use authorised drug products for COVID-19 treatment: an observational study.BMJ Open2025https://conductscience.org/library/papers/41093342PubMed
41004466Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study.PLoS One2025https://conductscience.org/library/papers/41004466PubMed
40879599A laboratory-focussed desk review of health systems in Uganda, Kenya, and the UK to respond to current and future pandemics.J Glob Health2025https://conductscience.org/library/papers/40879599PubMed
40864723Broad-spectrum synthetic carbohydrate receptors (SCRs) inhibit viral entry across multiple virus families.Sci Adv2025https://conductscience.org/library/papers/40864723PubMed
40861788Factors Influencing COVID-19 Viral Clearance: Implications for Vaccination and Antiviral Therapy.Infect Drug Resist2025https://conductscience.org/library/papers/40861788PubMed
40802235Design, synthesis and SARS-CoV‑2 main protease inhibitory activities of 2-arylthiomethyl-6-bromoindole derivatives.Mol Divers2026https://conductscience.org/library/papers/40802235PubMed
40741617Multitarget-based in silico screening from phytoactive compounds of Garcinia linii fighting toward severe acute respiratory syndrome coronavirus-2.Tzu Chi Med J2025https://conductscience.org/library/papers/40741617PubMed
40732341
Supercomputing Multi-Ligand Modeling, Simulation, Wavelet Analysis and Surface Plasmon Resonance to Develop Novel Combination Drugs: A Case Study of Arbidol and Baicalein Against Main Protease of SARS-CoV-2.
Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40732341PubMed
40437072Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection.Sci Rep2025https://conductscience.org/library/papers/40437072PubMed
40376119Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model: A Cross-Sectional Study on Self-Management, Information, and Medication Impact.J Patient Exp2025https://conductscience.org/library/papers/40376119PubMed

See all 231 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TMBIM451643PubTator's text mininghttps://conductscience.org/library/genes/51643

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35118917

GET https://conductscience.org/api/papers/v1/35118917/references?page=2